Study to Evaluate the Effect of CT1812 Treatment on Amyloid Beta Oligomer Displacement Into CSF in Subjects With Mild to Moderate Alzheimer's Disease

NCT03522129 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

3

Enrollment

INDUSTRY

Sponsor class

Conditions

Alzheimer Disease

Interventions

DRUG: CT1812
DRUG: Placebo

Sponsor

Cognition Therapeutics